Overall trial status: Ongoing, recruitment ended
Trial title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment
Medical conditions: Moderate to Severe Plaque Psoriasis
Status in each country: Germany:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, France:Ended
Trial phase: Therapeutic confirmatory (Phase III)
Therapeutic Areas: Diseases [C] - Immune System Diseases [C20]
Primary end point: IGA score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16., PASI 90 at Week 16.
Secondary end point: N/A
Age of participants: 0-17 years, 18-64 years, 65+ years
Gender of participants: Female, Male
Trial region: In both EEA and non-EEA
Planned number of participants: 281
Sponsor: Janssen - Cilag International
Sponsor type: Pharmaceutical company
Trial product: JNJ-77242113, Film-Coated Tablet without JNJ-77242113
Results posted: No
Overall decision date: 19/12/2023
Countries decision date: IT: 08/01/2024, FR: 03/01/2024, HU: 20/12/2023, ES: 22/12/2023, DE: 19/12/2023, PL: 21/12/2023
Last updated date: 19/08/2026
Es gibt noch keine Rezensionen.